1105056-24-3

Basic information

• Product Name: 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one
• Synonyms: 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one
• CAS NO: 1105056-24-3
• Molecular Weight: 450.447
• Mol File: 1105056-24-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one(1105056-24-3)
• EPA Substance Registry System: 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one(1105056-24-3)

Safety Data

• Hazardous Substances Data: 1105056-24-3(Hazardous Substances Data)

Upstream product

• 2051-90-3 Dichlorodiphenylmethane 
• 529-53-3 scutellarein 
• 27740-01-8 scutellarin 

Downstream Products

• 1402607-40-2 9-hydroxy-2,2-diphenyl-6-[4-(phenylmethoxy)phenyl]-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one 
• 1436402-36-6 C₃₄H₂₉NO₇ 
• 1619254-61-3 5-hydroxy-6,7-bis(methoxymethoxy)-2-[4-(phenylmethoxy)phenyl]-4H-1-benzopyran-4-one 
• 1619254-63-5 5-hydroxy-2-(4-hydroxyphenyl)-6,7-bis(methoxymethoxy)-4H-1-benzopyran-4-one 
• 1619254-65-7 5-hydroxy-6,7-bis(methoxymethoxy)-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4H-1-benzopyran-4-one 
• 529-53-3 scutellarein 
• 1436398-09-2 5,6,7-trihydroxy-2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4H-1-benzopyran-4-one 
• 6601-62-3 salvigenin 
• 520-12-7 pectolinarigenin 
• 6563-66-2 5,6,7-trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one 

Relevant articles and documents

Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway

To explore antitumor agents with potent efficacy and low toxicity, scutellarein derivatives with benzoic acid mustard (10a?c, 11a?c and 13a?c) were designed and synthesized. The antiproliferative activities of the target derivatives against A549, MCF-7 and Bel-7402 cancer cell lines were tested. Compound 10a showed the strongest potency with an IC50 value of 1.50 μM against MCF-7 cell line, and displayed low toxicity against human liver L-O2 normal cells (IC50 > 50 μM), showing specificity between normal and malignant cells. The mechanism studies revealed that 10a could induce apoptosis in MCF-7 cells, arrest MCF-7 cell cycle at the G1 phase and cause mitochondrial dysfunction in a concentration-dependant manner. Furthermore, the enhanced expression of the pro-apoptotic proteins caspase-9, caspase-3, Bax and cytochrome c, and the reduced expression of the anti-apoptotic protein Bcl-2 confirmed that 10a induced the intrinsic apoptosis pathway in MCF-7 cells. The potent antiproliferative activity and good selectivity guaranteed 10a a lead compound for the further development into anticancer therapeutics, especially for breast cancer.

Concise synthesis and antidiabetic activity of natural flavonoid glycosides, oroxins C and D, isolated from the seeds of Oroxylum indium

The first concise synthesis of natural flavonoid glycosides, oroxins C (1) and D (2), which were isolated from the seeds of Oroxylum indicum, was efficiently achieved by a convergent strategy. The synthesized natural products 1 and 2 were evaluated for th

Scutellarin aglycone nitrogen mustard derivative and preparation method and application thereof

The invention belongs to the field of natural medicine and medicinal chemistry and relates to a scutellarin aglycone nitrogen mustard derivative and a preparation method and application thereof, in particular to a scutellarin aglycone nitrogen mustard derivative of which 4'-OH is combined with benzoic acid nitrogen mustard and a preparation method and antitumor activity thereof. The structure of the scutellarin aglycone nitrogen mustard derivative and pharmaceutically acceptable salt thereof is as shown in the general formula I, wherein R and n are as described in claims and the specification.The formula I is shown in the description.